64
Participants
Start Date
May 17, 2011
Primary Completion Date
August 15, 2017
Study Completion Date
August 15, 2017
Carboplatin
AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.
Pemetrexed
500 mg/m2 by vein on day 1 of each 21 day cycle.
Bevacizumab
15 mg/kg by vein on day 1 of each 21 day cycle.
Cixutumumab
20 mg/kg by vein on day 1 of each 21 day cycle.
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
Eli Lilly and Company
INDUSTRY
Genentech, Inc.
INDUSTRY
M.D. Anderson Cancer Center
OTHER